ARPA-H contract will supercharge Every Cure’s work to identify existing medicines that can be repurposed to treat currently untreated diseases.
Initial progress utilizing a pilot version of the AI platform and stakeholder engagement has led to the identification of potential treatments for sickle cell disease, ALS, and autism spectrum disorder.
NEW YORK, Feb. 28, 2024 /PRNewswire/ — Every Cure, a nonprofit on a mission to save lives by repurposing existing medicines, announced today significant funding from the Advanced Research Projects Agency for Health (ARPA-H). The three-year, $48.3 million contract was unveiled at the White House this evening and represents a substantial federal investment in drug repurposing. It will accelerate Every Cure’s mission to unlock the full potential of existing drugs to treat more diseases through the development of an AI-powered platform, called ML/AI-enabled Therapeutic Repurposing In eXtended uses (MATRIX).
“I’m alive and in remission from my rare disease thanks to a repurposed drug that I discovered. While Ozempic is a recent example of drug repurposing, the concept is not new,” said David Fajgenbaum, MD, MBA, MSc, Co-Founder and President of Every Cure and Associate Professor of Medicine at the University of Pennsylvania. “Through Every Cure, we are working tirelessly to unlock the full potential of FDA-approved drugs to …